[go: up one dir, main page]

WO2011149310A3 - Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same - Google Patents

Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same Download PDF

Info

Publication number
WO2011149310A3
WO2011149310A3 PCT/KR2011/003919 KR2011003919W WO2011149310A3 WO 2011149310 A3 WO2011149310 A3 WO 2011149310A3 KR 2011003919 W KR2011003919 W KR 2011003919W WO 2011149310 A3 WO2011149310 A3 WO 2011149310A3
Authority
WO
WIPO (PCT)
Prior art keywords
rankl
rank
pharmaceutical composition
peptide
composition containing
Prior art date
Application number
PCT/KR2011/003919
Other languages
French (fr)
Korean (ko)
Other versions
WO2011149310A2 (en
WO2011149310A9 (en
Inventor
김경규
타민하이
황혜연
김낙성
진혜미
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Publication of WO2011149310A2 publication Critical patent/WO2011149310A2/en
Publication of WO2011149310A3 publication Critical patent/WO2011149310A3/en
Publication of WO2011149310A9 publication Critical patent/WO2011149310A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a novel peptide for inhibiting the interaction between RANKL and RANK, and a use thereof. The present invention provides a novel peptide for inhibiting the interaction between RANKL and RANK to inhibit the differentiation of osteoclast induced by RANKL, thereby providing a pharmaceutical composition for preventing or treating bone-related diseases caused by the differentiation and activation of osteoclast.
PCT/KR2011/003919 2010-05-27 2011-05-27 Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same WO2011149310A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0049467 2010-05-27
KR1020100049467A KR101180431B1 (en) 2010-05-27 2010-05-27 Peptide Inhibiting RANKL-RANK Interaction and Pharmaceutical Composition Comprising the Same

Publications (3)

Publication Number Publication Date
WO2011149310A2 WO2011149310A2 (en) 2011-12-01
WO2011149310A3 true WO2011149310A3 (en) 2012-04-19
WO2011149310A9 WO2011149310A9 (en) 2012-06-14

Family

ID=45004601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/003919 WO2011149310A2 (en) 2010-05-27 2011-05-27 Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same

Country Status (2)

Country Link
KR (1) KR101180431B1 (en)
WO (1) WO2011149310A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101465341B1 (en) 2013-06-18 2014-11-25 성균관대학교산학협력단 New peptide inhibiting rankl-rank interaction and the use thereof
KR101576904B1 (en) 2014-07-31 2015-12-14 (주)케어젠 Peptides Having Activities for Inhibiting Differentiation and Activity of Osteoclast and Uses Thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEATH, D. J. ET AL.: "An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma", CANCER RESEARCH, vol. 67, no. 1, 1 January 2007 (2007-01-01), pages 202 - 208 *
KIM, H. ET AL.: "Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 4, April 2009 (2009-04-01), pages 813 - 825 *
POBLENZ, A. T. ET AL.: "Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides", BIOCHEMCAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 359, 30 May 2007 (2007-05-30), pages 510 - 515 *

Also Published As

Publication number Publication date
WO2011149310A2 (en) 2011-12-01
KR101180431B1 (en) 2012-09-06
WO2011149310A9 (en) 2012-06-14
KR20110130044A (en) 2011-12-05

Similar Documents

Publication Publication Date Title
EA033343B1 (en) Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MD20150043A2 (en) Inhibitors of histone demethylases
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
WO2011005942A3 (en) Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
HK1210615A1 (en) Cystathionine-y-gamma-lyase (cse) inhibitors
EP4414376A3 (en) Novel depsipeptide and uses thereof
HK1210614A1 (en) Cystathionine-υ-lyase (cse) inhibitors
EP4403552A3 (en) C-terminal hsp90-inhibitors
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2013134353A8 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
MX2014001604A (en) Anthranilamide compounds and their use as pesticides.
MX2014001510A (en) Anthranilamide compounds and their use as pesticides.
WO2012017434A3 (en) Guanine nucleotide derivatives for treating bacterial infections
WO2012128521A3 (en) Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
WO2012116254A3 (en) Chrysophaentin analogs that inhibit ftsz protein
HK1205138A1 (en) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2012154879A3 (en) Autophagy inhibitors
WO2011149310A3 (en) Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same
WO2014070971A3 (en) Somatostatin-dopamine chimeric analogs
WO2013006526A3 (en) Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11786942

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11786942

Country of ref document: EP

Kind code of ref document: A2